Immediate and six months clinical and angiographic results of intracoronary paclitaxel-coated stent implantation – the Meo:DrugStar-1 study

Original Research

(1976) Views  (433) Full article downloads

Authors: Cihangir Uyan, Huseyin Arinc, Huseyin Gunduz, Ramazan Akdemir

Published Date March 2008 Volume 2008:4(1) Pages 173 - 176

DOI: http://dx.doi.org/10.2147/VHRM.S2203

Cihangir Uyan, Huseyin Arinc, Huseyin Gunduz, Ramazan Akdemir

Abant Izzet Baysal University, Izzet Baysal Medical Faculty, Cardiology Department, Bolu, Turkey

Abstract: The study was conducted to evaluate the clinical and angiographic results of the implantation of the paclitaxel-eluting stent Meo:DrugStar ST in patients with symptomatic coronary artery disease. The Meo:DrugStar ST stent has a stainless steel stent platform with a homogenous non-biodegradable coating of paclitaxel mixed with a polyether-based biostable, monophase, and hemocompatible coating. Sixty patients with native coronary artery disease were included in the study. The Meo:DrugStar ST stents were implanted in 60 de novo lesions detected in these patients. Immediate and long-term clinical and angiographic follow-up results were evaluated. There was a high proportion of patients with hypertension (55%) according to JNC-VII. Mean stenosis ratio was 78 ± 13 %, mean implanted stent diameter was 3.0 ± 0.4 mm and mean length was 22 ± 5 mm. Restenosis was detected in 4 (10%) of those patients and 11 (27.5%) of 40 patients had insignificant amount of restenosis.The results of this study indicate a potential benefit of the Meo:DrugStar ST stent for the prevention of stent thrombosis and restenosis in these relatively high-risk patients.

Keywords: Meo:DrugStar ST stent, paclitaxel drug-eluting stent, coronary artery disease

Other articles by Dr Cihangir Uyan